Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson stands out as a healthcare titan, known for its recession-resistant products, including pharmaceuticals and medical devices. With a solid dividend yield of 2.32% and impressive 1-year and 5-year returns of 46.43% and 39.40%, respectively, it offers a reliable option for investors seeking consistent income and growth potential. Analysts maintain a favorable outlook, assigning a median 12-month price target of $250 and a B+ rating, reflecting confidence in its robust market position.
Pros:
- Strong historical performance
- Diverse product offerings
Cons:
- Market competition in healthcare
- Regulatory risks
Johnson & Johnson (JNJ) may be suitable for investors seeking a blend of income and growth, particularly those who value stability in the healthcare sector. With a solid dividend yield and strong historical returns, it presents a compelling option for those looking to diversify their portfolios with a well-established company.